T. Peng

Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy

Q. Zheng, B. Liu, De-sheng Wang, 2019, OncoTargets and therapy.

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

Xia Li, Haifeng Zhao, Jia Fan, 2022, Cancer medicine.

Rare inborn errors associated with chronic hepatitis B virus infection *

P. Sham, Qibin Li, Qiulian Wu, 2012, Hepatology.

Bile in bronchi: A case report

Xinping Ye, Yongfei He, Tianyi Liang, 2020, Respiratory medicine case reports.

Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.

Jie Ma, Yan-Ming Jiang, T. Peng, 2023, Journal of Clinical Oncology.

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

H. Harputluoglu, S. Yoon, H. Marusawa, 2023, The Lancet.